Sobi: Presentation of Q4 and Full Year 2012 results

Sobi's interim report for the fourth quarter and full year 2012 will be published on 21 February 2013 at 8.30 a.m. CET. Conference call at 2.00 p.m. CET Financial analysts and media are invited to a telephone conference at 2.00 p.m. CET the same day, hosted by CEO Geoffrey McDonough, CFO Annika Muskantor and COO Alan Raffensperger. The presentation will be held in English and can be followed live or afterwards on our website www.sobi.com. Slides used in the presentation will be available on our website prior to the telephone conference. Details for participation Please call: SE: +46850556476 UK: +442033645371 US: +18776792993 Yours sincerely, Jorgen Winroth, VP Investor Relations Phone: +46 8 697 20 00 About Sobi Sobi is an international healthcare company dedicated to bringing innovative therapies and services to improve the lives of rare disease patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within hemophilia and neonatology. Sobi also markets more than 40 products for companies in the specialty and rare disease space. In 2011, Sobi had revenues of SEK 1.9 billion and around 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. Sobi Press Release on February 12, 2013, in PDF format: http://hugin.info/134557/R/1677450/547048.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE [HUG#1677450]